A population-based case-control teratologic study of furazidine, a nitrofuran-derivative treatment during pregnancy

Clin Nephrol. 2000 Apr;53(4):257-63.

Abstract

Objective: To study human teratogenic potential of furazidine treatment during pregnancy.

Design: Pair analysis of cases with congenital abnormalities and matched population controls.

Setting: The Hungarian Case-Control Surveillance of Congenital Abnormalities.

Participants: 38,151 pregnant women who had newborn infants without any defects (population control group) and 22,865 pregnant women who had newborns or fetuses with congenital abnormalities between 1980 and 1996.

Results: In the case group, 157 (0.7%) and in the control group, 254 (0.7%) pregnant women were treated with furazidine. The case-control pair analysis did not indicate a teratogenic potential of furazidine use during the second to third months of gestation, i.e. in the critical period for major congenital abnormalities.

Conclusion: Treatment with furazidine during pregnancy did not show teratogenic risk to the fetus.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Abnormalities, Drug-Induced / epidemiology*
  • Adult
  • Anti-Infective Agents, Urinary / adverse effects*
  • Case-Control Studies
  • Female
  • Furagin / adverse effects*
  • Humans
  • Infant, Newborn
  • Pregnancy
  • Pregnancy Complications, Infectious / drug therapy*
  • Urinary Tract Infections / drug therapy*

Substances

  • Anti-Infective Agents, Urinary
  • Furagin